A previous study by Baker A et al (JAMA 2023;177(3):240–247. Doi:10.1001/jamapediatris.2033.5258) demonstrated quite clearly that a 6-week course of intranasal mometasone furoate was as effective as intranasal saline for the treatment of symptoms of obstructive sleep-disordered breathing (SDB) in children. Both nasal sprays resulted in the resolution of symptoms in approximately 40% of participants. There was no control group, but previous smaller studies suggested an effect of both interventions. Their conclusions from the MIST study were that both options should be offered in primary care before referral to ENT clinics. It is worth a read. So, SDB is an overarching …